SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sagimet Updates Pipeline, Reports Phase 3 Acne Trial Underway

Sagimet Biosciences updated its investor presentation, noting an acne Phase 3 trial is underway and planning Phase 2 for TVB-3567. The presentation says funding is expected to support operations through mid-2029.

SGMT

Related stories